Health Economics›Non-small cell lung cancer›Advanced or metastatic disease second-line

Advanced or metastatic disease second-line

Non-small cell lung cancer · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cabozantinib monotherapy Variant #01	—	R 151 638	28d	4.3 mo	—	2	R 303 276 PFS proxy	1
Cabozantinib and Erlotinib Variant #01	—	R 74 562	28d	4.7 mo	—	2	R 149 124 PFS proxy	1
Docetaxel and Ramucirumab Variant #01	—	R 62 164	21d	—	10.5 mo	2	R 124 328 PFS proxy	1
Carboplatin and Pemetrexed Variant #01	—	R 14 563	21d	3.5 mo	—	3	R 43 688 PFS proxy	1
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	2.9 mo	8.3 mo	9	R 119 025 PFS proxy	9
Gefitinib monotherapy Variant #01	—	R 4 278	28d	3.4 mo	7.6 mo	2	R 8 556 PFS proxy	6
Docetaxel monotherapy Variant #02	—	R 2 921	28d	3.2 mo	9.8 mo	8	R 23 372 PFS proxy	39
Docetaxel and Vandetanib Variant #01 Partial	—	R 1 948	21d	4.0 mo	—	7	R 11 686 PFS proxy	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	9.5 mo	7	R 11 705 PFS proxy	1
Vinflunine monotherapy Variant #01 Partial	—	—	21d	2.3 mo	—	2	—	1

10 of 10 regimens shown